Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …

Tumor mutational burden correlates with response to immune checkpoint blockade in
multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain …

Therapeutic antibodies blocking programmed death-1 and its ligand (PD-1/PD-L1) induce
durable responses in a substantial fraction of melanoma patients. We sought to determine …

Anti-PD-1 therapy yields objective clinical responses in 30–40% of advanced melanoma
patients. Since most patients do not respond, predictive biomarkers to guide treatment …

Monoclonal antibodies directed against cytotoxic T lymphocyte–associated antigen-4 (CTLA-
4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic …

Outcomes for patients with melanoma have improved over the past decade as a result of the
development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte …

Association with hypomethylating agents is a promising strategy to improve the efficacy of
immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation …

Background Immune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1
antibodies is standard treatment for metastatic melanoma. Anti-PD-1 (pembrolizumab …

Purpose: In contrast to the predominant chronic UV exposure–induced cutaneous
melanoma in Caucasians, acral and mucosal comprise the majority of melanomas in Asia …